SCHEMBL17867476

SCHEMBL17867476

COc1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(Oc6ccnc7cc(OCc8ccccc8)c(OC)cc67)c(F)c5)CC4)cc3F)ccnc2cc1OCc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 16/20 0.77
KDR P35968 6/20 0.77
AXL P30530 5/20 0.77
MERTK Q12866 3/20 0.70
FLT3 P36888 4/20 0.68
RET P07949 3/20 0.68
KIT P10721 3/20 0.68
HDAC2 Q92769 2/20 0.68
HDAC8 Q9BY41 2/20 0.68
HDAC6 Q9UBN7 2/20 0.68
PDGFRB P09619 2/20 0.68
HDAC10 Q969S8 1/20 0.67
HDAC11 Q96DB2 1/20 0.67
AURKB Q96GD4 4/20 0.64
FLT1 P17948 3/20 0.64
AURKA O14965 2/20 0.64
RIPK2 O43353 2/20 0.64
ABL1 P00519 2/20 0.64
EGFR P00533 2/20 0.64
ERBB2 P04626 2/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17867475 0.98 MET (0.73) METKDRAXLMERTKFLT3
SCHEMBL29693523 0.97 MET (0.83) METKDRAXLMERTKFLT3
SCHEMBL29693522 0.97 MET (0.83) METKDRAXLMERTKFLT3
SCHEMBL4401192 0.97 MET (0.83) METKDRAXLMERTKFLT3
SCHEMBL19372980 0.96 MET (0.74) METKDRAXLMERTKFLT3
SCHEMBL31412953 0.92 MET (0.65) METKDRAXLMERTKFLT3
SCHEMBL371999 0.89 MET (0.78) METKDRAXLMERTKFLT3
SCHEMBL10449248 0.89 AXL (0.76) METKDRAXLMERTKFLT3
SCHEMBL24240662 0.88 AXL (0.72) METKDRAXLMERTKFLT3
SCHEMBL17884997 0.88 MET (0.62) METKDRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160185725-A1 c-Met Modulators and Method of Use EXELIXIS, INC. 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185725-A1 c-Met Modulators and Method of Use FLT4, MET, FLT1 MET 2/4885KDR 5/4885AXL 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.